(Q38816901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

title

Defining actionable mutations for oncology therapeutic development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

author name string

Robert McEwen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Brian Dougherty

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Justin H Johnson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Jonathan R Dry

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Zhongwu Lai

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Zara Ghazoui

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Naomi M Laing

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Darren R Hodgson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Francisco Cruzalegui

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

Simon J Hollingsworth

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

J Carl Barrett

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

language of work or name

English

0 references

publication date

1 April 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

3 April 2020

page(s)

319-329

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27112209%20AND%20SRC:MED&resulttype=core&format=json

Non-small-cell lung cancer.

3 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Implementing personalized cancer genomics in clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Designing transformative clinical trials in the cancer genome era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Prioritizing targets for precision cancer medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Precision medicine in oncology drug development: a pharma perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Exceptional Responders Inspire Change: Lessons for Drug Development From the Bedside to the Bench and Back

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Patient-centric trials for therapeutic development in precision oncology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Technical and implementation issues in using next-generation sequencing of cancers in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Absolute quantification of somatic DNA alterations in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Personalized genomic analyses for cancer mutation discovery and interpretation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

31 March 2020

Cancer genome landscapes

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The landscape of somatic copy-number alteration across human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The emerging complexity of gene fusions in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Somatic mutations lead to an oncogenic deletion of met in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The breast cancer information core: database design, structure, and scope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Splicing in action: assessing disease causing sequence changes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Discovery and saturation analysis of cancer genes across 21 tumour types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The Cancer Genome Atlas Pan-Cancer analysis project

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

International network of cancer genome projects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Cancer gene expression signatures - the rise and fall?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

ClinGen--the Clinical Genome Resource

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Comparison of predicted and actual consequences of missense mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

An integrated map of genetic variation from 1,092 human genomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

A decision support framework for genomically informed investigational cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

NCI-MATCH launch highlights new trial design in precision-medicine era

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.35

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27112209